This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Diagnosis of a relapsed/refractory hematologic malignancy
Age ≥ 18 years
Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
Age < 18 years
Already enrolled in hospice
Resides in nursing home or assisted living facility
History of previous serious adverse transfusion reaction
Dana-Farber Cancer Institute
Lead sponsor
National Cancer Institute (NCI)
Collaborator